Shots:
The company has decided to discontinue the P-IIb/III study evaluating dipraglurant in patients with dyskinesia associated with PD-LID
The discontinuation is due to the slow recruitment of patients. Additionally, the company intends to concentrate on advancing its preclinical portfolio to the clinic and pursuing strategic collaborations for specific programs
The results from the P-II study of ADX71149 in epilepsy patients are expected in Q4’22. Addex’s ADX71149 is currently in a P-IIa PoC clinical trial for epilepsy. Indivior PLC has licensed Addex’s GABABPAM program for drug candidate development with a focus on substance use disorder
Ref: Globenewswire | Image: Addex
